State-of-the-art science, developed in partnership with some of the UK’s top universities. The test gives you an accurate and non-invasive genetic risk evaluation for Alzheimer’s disease.

Giving you access to science that is normally reserved for clinical research, genoSCORE-ACT provides you the power to discover your personal risk of Alzheimer’s by analysing over 100,000 genetic variations in your DNA that are associated with, or protective against, the disease. More than any other genetic test on the market. We think of it as APOE Plus†.

Learn the science behind genoSCORE-ACT

Worried you might be at risk for Alzheimer’s disease?

genoSCORE-ACT uncovers what’s written in your genes.

What's included?

User instruction booklet

OraCollectⓇ-DNA OCR-100 saliva collection device

Sample return bag and free postage to our lab

You get results within 4-6 weeks of your sample arriving at our lab

Download your personal report from our secure server

Arrange a free session with a counsellor to discuss your results

Please be aware that genoSCORE-ACT should only be used by people with European ancestry. We are working hard to validate genoSCORE technology in other ethnicities.

genoSCORE-ACT gives you the reassurance to know you’re making the best decisions for your long-term brain health

"We had mixed feelings about the test results. While it was reassuring to know that one of us was at average risk, knowing that Helen is high-risk did cause considerable concern. However, we saw the result as an opportunity to focus on our lifestyle choices and improve our general health, as this has been shown to reduce Alzheimer’s risk.”


"Polygenic risk testing, such as genoSCORE-ACT, could be used at the earliest possible time to identify those most likely to benefit from future interventions, including lifestyle and environmental risk changes and management of related illnesses that affect the development of Alzheimer’s”

Professor Sir John Hardy, Group Leader at the UK Dementia Research Institute, University College London

genoSCORE-ACT also has a role in clinical research

The test is used in an important NHS study carried out by The National Institute for Health & Care Research to identify those at risk for Alzheimer’s disease.

Professor Dag Aarsland, Chair of Old Age Psychiatry, Institute of Psychiatry, Psychology & Neuroscience, King’s College, London, is the principal investigator of this study and a leading academic clinical expert in Alzheimer’s disease. 

We’re constantly striving to improve

We continue to develop our genoSCORE technology. This includes working with data from the PROTECT study, a major long-term research programme run by the University of Exeter and King’s College, London in partnership with the NHA, that aims to understand how healthy brains age and why people develop dementia.

The global PROTECT study was developed by Professor Clive Ballard, Executive Dean and Pro-Vice-Chancellor of the University of Exeter Medical School, a leading academic clinical investigator in Alzheimer’s disease.

Professor Ballard explains, “We know dementia risk can be reduced by one-third through improving lifestyle factors from midlife. This study will provide valuable information about how the brain changes with age, which combination of factors such as exercise and diet really work, and how we can best encourage people to adopt these changes.”

For more information go to:

Reasons why genoSCORE-ACT may be the right choice for you

genoSCORE-ACT gives you the power to understand your Alzheimer’s risk. You may be concerned about a family history and looking for peace of mind.

Alzheimer’s has a devastating impact on people’s lives - sufferers, their families and friends - and that’s something we care passionately about.

Driven by our mission, we make scientific advances that would normally be reserved for clinical research available to ordinary people.

Worrying about your risks of developing Alzheimer’s disease

Get tested using the genoSCORE-ACT genetic risk test

Kick start your action plan by making simple lifestyle adjustments

The majority of people have low or medium genetic risk for Alzheimer’s disease*

Getting tested let’s you know what’s written in your genes.

Proud to have collaborated with:

Convenient, easy-to-use test kit sent to your door

Testing done in our UK laboratory

Results within 4-6 weeks of your sample arriving at the lab

How do I get tested for Alzheimer’s disease risk?

  1. Order the genoSCORE-ACT test via our website

  2. Register your test kit on using the barcode on the saliva collection device

  3. Put your saliva sample in the packaging provided and send it to our lab

  4. You will get an email that will let you know your personal risk report is available to download from our secure server 

How does the genoSCORE-ACT genetic risk test for Alzheimer’s disease work?

When we receive your sample, our scientists extract the DNA from your saliva. They calculate your personal risk score by evaluating the genetic variations that can increase the risk of Alzheimer’s disease and those provide a protective effect using our proprietary software. You receive an easy-to-understand report containing your personal risk score. The price of the test also includes an optional virtual counselling session giving you a chance to discuss your personal risk score and learn more about managing your brain health.

Please be aware that genoSCORE-ACT should only be used by people with European ancestry. This is because the test process was developed using what is known as a biobank. This is a collection of DNA samples including from people with clinically diagnosed Alzheimer’s disease. Most of the samples in the biobank came from people of European descent (sometimes known as Caucasian individuals). For that reason, the test should only be used by individuals with similar ancestry. We are working on validating genoSCORE technology in other ethnicities.

*Data on file, Cytox Limited
†You may be familiar with a genetic test called APOE that is considered a way to assess risk for Alzheimer’s disease. APOE refers to a single gene – Apolipoprotein E – a particular type of which (E4) has been associated with an elevated risk for AD. Rather than look at a single gene, genoSCORE-ACT assesses over 100,000 genetic variations in your DNA to generate a comprehensive evaluation of your personal genetic risk. If you’re keen to know your APOE genotype, don’t worry, we also include this in your personal risk score report, so no need to have a separate APOE test.